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Abstract
Background: Colorectal cancer (CRC) screening programmes using a guaiac faecal oc-
cult blood test (gFOBt) reduce CRC mortality. Interval cancers are diagnosed between 
screening rounds: reassurance from a negative gFOBt has the potential to influence 
the pathway to diagnosis of an interval colorectal cancer.
Methods: Twenty- six semi- structured face- to- face interviews were carried out in 
Scotland and England, with individuals diagnosed with an interval colorectal cancer 
following a negative gFOBt result.
Results: Participants reported they were reassured by a negative gFOBt, interpreting 
their result as an “all clear”. Therefore, most did not suspect cancer as a possible cause 
of symptoms and many did not recall their screening result during symptom appraisal. 
Among those who did consider cancer, and did think about their screening test result, 
reassurance from a negative gFOBt led some to “downplay” the seriousness of their 
symptoms with some interviewees explicitly stating that their negative test result con-
tributed to a delayed decision to seek help.
Conclusion: Screening participants need to be informed of the limitations of screening 
and the ongoing risk of developing colorectal cancer even when in receipt of a nega-
tive result: the importance of minimizing delay in seeking medical advice for colorectal 
symptoms should be emphasized.
K E Y W O R D S
colorectal cancer screening, interval cancer, negative screening result, symptom appraisal, 
help-seeking, understanding of screening
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1  | INTRODUCTION
In the UK and other high- income countries, colorectal cancer (CRC) 
is a leading cause of cancer- related mortality.1,2 Population- based 
CRC screening programmes have been introduced in a number of 
countries and have been shown to reduce CRC mortality.3 Since 
2006, the UK has introduced CRC screening programmes based on 
the guaiac faecal occult blood test (gFOBt), with colonoscopy of-
fered to those who receive a positive result. UK programmes are 
currently switching to use of faecal immunochemical testing (FIT). 
Following a successful trial,4 the UK is also currently implementing 
national flexible sigmoidoscopy screening programmes that will run 
alongside existing biennial screening.
Despite CRC screening programmes being in place, uptake of 
CRC screening in the UK is approximately 55% and the majority 
of CRC cases will present symptomatically.5-9 Furthermore, gFOBt 
screening is associated with a high proportion of interval cancers: 
between 30% and 50% of all CRCs detected in the screened pop-
ulation in the Scottish and English pilot programmes.10,11 Interval 
cancers include cancers that have developed between screening 
rounds and “missed” cancers following a false- negative screen-
ing result; they have poorer survival when compared to screen- 
detected CRC.12-14
A number of studies report that people who experience poten-
tial cancer symptoms rarely initially interpret them as such, often 
normalizing symptoms or attributing them to something else.2 The 
Model of Pathways to Treatment is a conceptual framework devel-
oped to describe the complexity of pathways leading to a cancer 
diagnosis and defines the processes within 4 key intervals (ap-
praisal, help- seeking, diagnostic and pre- treatment) comprising key 
events from the detection of a bodily change through to the start 
of treatment.15,16 The patient interval encompasses appraisal and 
help- seeking.17 Evidence suggests that one of the main factors con-
tributing to a long patient interval is non- recognition of symptom 
seriousness resulting in increased time to presentation and diag-
nostic delay.18,19
Previous reassurance from a healthcare provider for a similar 
symptom or receipt of a previous “all clear” diagnosis has been 
associated with delays in help- seeking for potential cancer symp-
toms.20,21 We and others have reported that participation in the 
NHS bowel screening programmes has the potential to lead to a 
delay in help- seeking for some patients following the onset of symp-
toms, through over- reassurance from a negative gFOBt result.22,23 
Unintended consequences, including over- reassurance, from a neg-
ative or “normal” result have been demonstrated in breast cancer 
and other screening programmes.24-26
The aim of this study was to explore, through individual inter-
views with screening participants who were diagnosed with an in-
terval colorectal cancer, if receiving a negative screening result in 
a CRC screening programme contributed to their subsequent re-
sponse to symptoms potentially indicative of cancer, and their deci-
sion to seek medical advice.
2  | METHODS
2.1 | Design
Semi- structured individual face- to- face interviews were carried out 
with patients diagnosed with an interval colorectal cancer following 
a negative gFOBt result through colorectal cancer screening (bowel 
screening programmes). Interviews were carried out within 6 months 
of patients receiving their cancer diagnosis.
2.2 | Setting and recruitment
All patients newly diagnosed with a primary colorectal cancer and 
who had received a negative gFOBt result (within the preceding 
two years) from the Scottish bowel screening programme or the 
Midlands and North West screening programme hub were eligible 
to take part in the study. Eligible screening age for the two respec-
tive programmes was 50–74 years (Scotland) and 60–74 years 
(England). This study selected patients using a purposive approach, 
recruiting patients via the hospital clinic where they received or 
were currently receiving their cancer treatment in NHS Tayside, 
Scotland, and University Hospitals Coventry & Warwickshire NHS 
Trust, England. Lists of patients, reviewed by the multidisciplinary 
teams (MDT) following a colorectal cancer diagnosis, were sent 
quarterly to the local screening hub in Dundee, Tayside or Rugby, 
North West Midlands. Confirmation of receipt of a negative gFOBt 
result was confirmed through checking screening hub records, and 
the patient list was returned to the colorectal surgeon responsible 
for the patient’s care.
Patient invitation letters were sent directly to the patient from 
the secondary care team on behalf of the research team, including a 
participant information booklet, response form and prepaid addressed 
return envelope. Once a response form was received by the researcher 
(KB), individuals were contacted by telephone to arrange a suitable 
time and date for the interview.
2.3 | Exclusion criteria
Suitability based on clinical grounds (physical or mental health) was at 
the discretion of the secondary care team and primarily the patient’s 
colorectal surgeon in charge of their care.
2.4 | Data collection
Interviews were carried out by a female researcher, KB (MA, MSc, 
PhD), with previous training and experience in conducting qualita-
tive research. Interviews took place between August 2013 and June 
2014. Interviews lasted between 45 and 60 minutes, and signed con-
sent was obtained before the interview commenced. All interviews 
were audio- recorded with the participant’s permission, professionally 
transcribed verbatim and anonymized. Field notes were made both 
during and after each interview. Audio files were deleted once the 
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written transcripts had been received and verified by the researcher. 
Interviews took place in the patient’s home, and some patients were 
accompanied by their spouse or friend during the interview.
2.5 | Topic guide
Interviews explored two key domains: (i) the participant’s “pathway 
to diagnosis” including: initial symptom appraisal, symptom progres-
sion, first presentation to any healthcare provider and any perceived 
delays, and (ii) the contribution, if any, of their negative gFOBt result 
to their symptom appraisal or decision to seek help.
2.6 | Ethical review
The project was granted ethical approval from the South East Scotland 
Research Ethics Committee 01 (11/SS/0006).
2.7 | Analysis
All transcripts were read by both the project researcher (KB) and the 
principal investigator (CC). Emerging themes were discussed and a 
coding frame agreed with additional codes included when appropri-
ate as data collection progressed. Final themes were agreed through 
an iterative process involving the core and wider research group. 
Thematic analysis of the data was undertaken using NVivo software 
(QSR International, V.10) and was ongoing throughout the study to 
allow emerging themes to be fed back into the data collection. An 
inductive reasoning approach was adopted where themes (or catego-
ries) were identified through careful examination and comparison of 
the data which involved 6 stages: familiarization of the data, generat-
ing initial codes, searching for themes, reviewing themes, defining and 
naming themes and producing a report.27
3  | RESULTS
3.1 | Recruitment
A total of 27 participants were recruited, with 17 interviews carried 
out in Tayside, Scotland, and 10 in the Midlands and North West, 
England. Recruitment was ongoing throughout the study; 50% of pa-
tients who received an invitation to take part in the study agreed to 
be interviewed. Twenty- one participants presented to their GP with 
symptoms prior to their diagnosis, two attended their GP for a rou-
tine diabetic health check, one participant was diagnosed following an 
emergency admission to hospital and two participants were diagnosed 
following a surveillance colonoscopy. One participant, wrongly identi-
fied, had received a positive gFOBt result in the screening programme, 
which led to their diagnosis: this interview was not included in the 
reported findings. A summary of study recruitment and participant 
demographics is provided in Table 1.
3.2 | Reported symptoms
Participants described a range of symptoms and symptom characteris-
tics, which differed in frequency, duration and severity prior to receiv-
ing their colorectal cancer diagnosis. Reported symptoms included: 
noticeable blood on toilet paper or in the toilet bowl or stool following 
a bowel movement, constipation and/or diarrhoea, change in bowel 
habit, weight- loss, indigestion, nausea and sickness, fatigue and pain. 
Participants who were diagnosed following a routine diabetic health 
check reported that they did not experience any symptoms preceding 
their cancer diagnosis.
3.3 | Main themes
We found the relationship between a negative gFOB result and a pa-
tient’s diagnostic journey to be multifaceted, with varying opportuni-
ties or scenarios in which screening participation and the receipt of 
a negative result had the potential to influence the appraisal interval 
following the onset of symptoms (Figure 1). We identified three key 
stages where a negative gFOBt result had the potential to contribute 
to the appraisal and/or help- seeking interval outlined in the Model of 
Pathways to Treatment,15 and a fourth stage where participants re-
flected on their screening participation following their interval colorec-
tal cancer diagnosis. The potential impact of a negative gFOBt result 
at each stage was influenced by a number of emergent and cross- 
cutting themes: (i) receipt of a negative screening (gFOBt) result (Trust 
and Reassurance), (ii) recall of a negative test result following the onset 
of symptoms (Cancer Suspicion and Time Since Last Screen), (iii) the sub-
sequent contribution, if any, of a negative gFOBt result to symptom 
response (Extended Symptom Appraisal & Delayed Help-seeking) and (iv) 
reflection on the bowel screening programme following an interval 
TABLE  1 Recruitment summary—interviews with interval bowel cancer patients in Tayside, Scotland, and North West Midlands, England
Interviews (N) Location Response rate (%) Male (%) Age range Route to diagnosis (N)
17 Tayside, Scotland 17/33 (51) 9 (53) 52- 77 GP (15)
Emergency Admission (1)
Surveillance Colonoscopy (1)
10 (9*) North West 
Midlands, England
10/21 (45) 6 (60) 63- 75 GP (8)
Surveillance Colonoscopy (1)
Positive gFOBt (1)*
*One patient transcript was not included in subsequent analysis due to a recruitment error—diagnosed following a positive guaiac faecal occult blood test 
(gFOBt).
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colorectal cancer diagnosis (Knowledge/Acceptance of the Limitations 
of gFOBt screening). These 4 key stages including the emergent themes 
and subthemes are shown in Figure 1.
3.4 | Response to receipt of a negative gFOBt result
3.4.1 | Trust and Reassurance
Screening participation was associated with low levels of apprehen-
sion, with the receipt of a negative test result leading to positive 
emotions such as pleasure and relief. For some participants, who felt 
well and perceived themselves to be healthy, a negative result was 
simply confirmation of their health status. Participants portrayed a 
high degree of confidence and trust in their negative screening result 
describing it as “an all clear” that they “were ok” or that they had 
“passed.” Participants did not question the reliability of the test result 
when they received their result letter although some participants, 
following more in- depth reflection, acknowledged the information or 
disclaimer, provided with the screening materials promoting symp-
tom vigilance and help- seeking between screening episodes.
I just thought that’s good, I’ve got the all clear, I wasn’t 
worried between sending it off and waiting on the letter to 
come back, I never actually gave it too much thought but 
obviously it’s good to get the all clear. 
(Male, Tayside #02)
… they say it’s fine so you take their word for it, they’ve 
done the tests… that’s it until the next time it comes round 
and you just carry on. 
(Female, Tayside #01)
I did trust the thing, you know, the sample [gFOBt result], 
because I did, I’d sent them back, you know, and I always 
got a letter come back to say they were negative. 
(Female, Midlands #02)
Most participants did not recall experiencing symptoms when they 
completed their gFOBt. For a proportion of patients, the presence of 
symptoms contributed to their decision to participate. Among those 
who reported that they had symptoms when completing the test, or 
had been experiencing symptoms intermittently, a negative gFOBt re-
sult provided some degree of reassurance with regard to the serious-
ness or urgency of their symptoms.
I guess I had some reassurance from the fact that the 
screening tests had proved negative… I guess it made 
me feel that, okay, there is nothing drastically wrong at 
the minute. So I needn’t, I needn’t worry myself about it. 
Without fully appreciating, I suppose, what the screening 
test can and can’t do. 
(Male, Midlands #03)
I took comfort each time [when he received a negative 
result]. I thought, there’s nothing there so it can’t be 
[cancer]. It must be alright… so it was a false reassur-
ance, but as I say, it does say clearly on the letter, if you 
have any of these other symptoms, erm, go and see your 
doctor. 
(Male, Tayside #11)
3.5 | Recall of negative gFOBt result following the 
onset of symptoms
3.5.1 | Cancer suspicion
We found that recall of participation in the colorectal screening pro-
gramme, during symptom appraisal, was a key determinant in ascertain-
ing whether receipt of a negative gFOBt result contributed to the patient 
interval. Among the interviewees, recall of their negative screening re-
sult was largely dependent on whether or not cancer was considered, 
even briefly, as a potential cause of their symptoms. Cancer suspicion 
and the recall and consideration of their gFOBt result were further influ-
enced by a number of emergent subthemes including the characteristics 
of their experienced symptoms, competing diagnoses (or causal beliefs) 
and the presence of either a personal or family history of cancer.
Many participants reported that they did not recall, or think 
about, their negative screening result during the symptom appraisal 
interval and did not consider cancer as a potential cause of their 
symptoms. This was particularly evident among participants who 
described symptoms that were not readily associated with the 
bowel, for example feeling tired, acid reflux or hip pain, or when 
the cause of symptoms was assumed to be attributable to a benign 
cause (or a competing diagnosis), for example haemorrhoids or a 
stomach bug. Often during initial symptom appraisal, patients “nor-
malized” or justified their symptoms, ascribing them to ageing or 
simply “overdoing” it.
We’d had bowel screening tests, or I had, the year before… 
I think it was, I can’t remember offhand. And it was clear, 
so you sort of put that out of your mind, you know, out of 
the way. And I’d no change in my bowel habits… I think if 
my bowel movements had been erratic, or something, then 
I might have connected it somehow, I don’t know. But it 
was so far over here [the pain], you know, I just thought 
it was my hip. 
(Female, Midlands #09)
Well, I didn’t know, I never even thought of cancer, it just 
didn’t enter my head; I just thought maybe I’d got internal 
piles or, you know, haemorrhoids, um, or, um, a, a fissure 
that was deep in, you know, inside; and never, ever gave it 
a thought that it could be a cancer, not at all. 
(Female, Midlands #01)
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I put a lot of my problems down to tiredness, to age- related 
as well. Simple as that, yeah. 
(Male, Midlands #10)
However, a smaller group of interviewees explicitly remembered 
considering their previous negative gFOBt result following the onset 
of their symptoms. These patients suggested that they suspected, 
or at least considered, colorectal cancer as a possible cause of their 
symptoms and/or were experiencing bowel- associated symptoms ei-
ther intermittently or at the time that they carried out their screening 
test. When symptoms persisted, increased in severity or additional 
symptoms developed, these participants applied a more serious 
illness label and/or suspected cancer as a possible cause of their 
symptoms. Similarly, participants with a personal or family history 
of cancer were more likely to attribute their symptoms to a potential 
cancer diagnosis.
I just put it down to constipation, like, you know? I 
wasn’t getting heavy bleeding or anything like that, 
you know? So, It was only when I started getting 
these pains in the stomach that I started to think, well 
maybe this could be something worse… (Male, Tayside 
#08)
I had a family history of bowel cancer on my father’s side 
and in the back of my mind right from the start it just… I 
thought, you know… this was the same symptoms that he 
had had… 
(Female, Tayside #05)
3.5.2 | Time since last screen
There was some evidence to suggest that patients who had recently 
participated in colorectal screening, prior to the onset of symptoms, 
for example in the preceding few months, were more likely to reflect 
on their negative screening result and recall the information provided 
with the result letter.
Every two years you have, like, a little pack come through 
the post and you’re tested for that. And I’d not long com-
pleted one, so I assumed that it was nothing like that. I 
mean, the results had come back clear… 
(Male, Midlands #08)
I think because eh possibly [the] best part of two years 
had passed and [I] hadn’t really read the literature, the 
F IGURE  1 The contribution of a negative guaiac faecal occult blood test (gFOBt) result—identified themes and subthemes from patient 
accounts of their pathway to diagnosis of an interval colorectal cancer
Patient symptom appraisal and help-seeking interval
The contribution of negative gFOBt result to the pathway of an interval colorectal cancer diagnosis.
Colorectal
screening
participation
Response to
the receipt of 
a negative 
gFOBt reslut
Recall of 
negative gFOBt
result
Contribution of
negative gFOBt
result to
symptom
response
Diagnosis
(reflection on
screening
participation
post-diagnosis)
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information more recent, that I was [wasn’t] aware of what 
was going on, if it happened just after I’d done the bowel 
screening a short period of time possibly after I might have 
been more aware but the information hadn’t probably reg-
istered and stuck. 
(Male, Tayside #02)
3.6 | The subsequent contribution, if any, of a 
negative gFOBt result to symptom response
3.6.1 | Extended symptom appraisal and delayed 
help- seeking
Among the interviewees who considered their gFOBt result during 
the appraisal interval, there was a clear indication that for some, 
receipt of a negative gFOBt result contributed to an extended 
symptom appraisal interval, which in turn led to a delayed decision 
to seek help. Recall of a negative screening result helped to reas-
sure participants by reinforcing pre- existing “benign” causal beliefs 
(subtheme) and/or reducing any cancer suspicion, believing that 
colorectal cancer would be an unlikely cause of their symptoms 
having recently received an “all clear” from the bowel screening 
programme.
… because of thinking it was just a fissure, um, I automat-
ically thought, well, if there was anything wrong it would 
show up in the screening, so it must be just a fissure. 
(Female, Midlands #01)
I didn’t think that it could go wrong, you know. I just… I 
was really stressed at the time that this all happened, be-
cause of my sister [also had cancer diagnosis] but I was 
stressed then, before it all started with me, you know, I was 
stressed out, I thought, oh, God, I’m just you know, really 
worried now, I hope nothing’s going to happen to me. And 
I think to myself, no, it can’t, because I’ve had the tests, 
you know. 
(Female, Midlands #02)
I did assume that it was something else to start with cos 
I didn’t consider, obviously at the back of your mind it 
is there [the possibility of it being cancer] but you think 
well, you had the screening it will probably be something 
else. 
(Female, Tayside #04)
Some participants were more explicit in their accounts that the re-
assurance provided by their negative test result contributed to them 
“downplaying” the potential severity or urgency of their symptoms. 
However, there was no strong indication that receipt of a negative result 
was the primary (or sole) driver for delaying consulting with a GP. It was 
described more as a contributing factor to the appraisal and help- seeking 
interval in which a number of other factors and competing demands, 
such as caring for a spouse or going on holiday, influenced the timing of 
their decision to seek help.
I was going away to America; we were having a family hol-
iday. We went to America, Disney World, ten of us, for two 
weeks, and I thought, well, I’ll go back and see the doctor 
after I come back. 
(Female, Tayside #13)
For others, who were already more reluctant to seek help despite 
suspecting that their symptoms could be attributable to something seri-
ous, receipt of a negative gFOBt result provided an excuse to continue to 
ignore symptoms or allowed participants to justify (to themselves) their 
decision to delay seeking help.
[reflecting on having done the screening result a few 
months before] so I thought ‘och no ken it will be some-
thing else’, so I suppose I left it for longer than I should have 
just partly because I was always running about, but then 
eventually I went to the GP… 
(Female, Tayside #04)
Thinking back there’s always perhaps a bit of wishful think-
ing, oh the test’s okay then I don’t need to worry about it. 
(Male, Midlands #03)
I mean, the results had come back clear… the screening 
do warn you that, um… the screening test did warn you 
that if you get any of these other problems, you should go 
to your GP… and, I mean, I just allowed that to be another 
excuse not to go. 
(Male, Midlands #08)
In contrast, one participant who presented promptly to the GP 
following an episode of bleeding attributed their prompt response to 
recalling the information contained within the screening result letter 
regarding symptom vigilance and advice on when to consult with a 
GP.
Because, they said that in the pamphlet, like, any signs of 
bleeding and all that shouldn’t be ignored, like, you know? 
And, that’s the reason I went up, just to make sure that I 
was okay. 
(Male, Tayside #08)
It’s important to note that although a small number of patients were 
influenced by their negative test result, most interviewees believed that 
they presented promptly to their GP following the onset of symptoms 
(generally within a number of days or weeks). Early recognition of symp-
toms was usually followed by a short period of self- monitoring where 
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participants adopted a “watch and wait” approach to see if symptoms 
resolved by themselves. Generally, when symptoms persisted or pro-
gressed in severity, or following a period of self- treatment using over- 
the- counted medications, for example for suspected haemorrhoids or 
constipation, participants chose to consult with a GP or HCP.
I just thought I’ll wait a few weeks and see if it’s… see if it 
improves and I was using proprietary stuff, you know. Erm, 
that I bought out the chemist. 
(Male, Tayside #15)
The presence of pre- existing conditions or comorbidities and their 
treatment (prescribed or over- the- counter medications) was associated 
with an extended appraisal and diagnostic interval. This was evident 
among participants independent to any reflection on previous screening 
participation during their symptom appraisal. The impact of comorbidity 
on the pathway to diagnosis was two- fold: (i) some participants reported 
that they attributed their new symptoms to a pre- existing diagnosis and 
therefore did not seek immediate advice or view the symptoms as se-
rious, and (ii) once a decision had been made to seek help, referral to 
secondary care was sometimes delayed due to an initial focus, both by 
the patient and by the GP, on alternate treatments or investigations for 
a pre- existing condition.
Well, I’ve got MS as well, you see so sometime I’ll be think-
ing the headaches and that or the dizziness, ‘cause that’s 
one of the things I had when I had the MS… oh I had a real 
dizzy spells, … so I was thinking it was that [laugh]. 
(Male, Tayside #12)
Yeah, I was thinking, oh, it’s my Fibregel playing up and then 
we changed to the Movicol [history of bowel prolapse], I 
think I went two or three times [to see GP], because we 
tried… we tried Movicol and we tried, erm, something else 
with Senna… and we tried that for, like, a couple of weeks 
and it wasn’t getting any better. 
(Female, Midlands #07)
3.7 | Reflection on the bowel screening programme 
following an interval colorectal cancer diagnosis
3.7.1 | Knowledge/acceptance of the limitations of 
gFOBt screening
While some participants recalled their negative gFOBt result during 
the appraisal interval, others only considered their participation in the 
colorectal screening programme after they had received their cancer 
diagnosis. These participants tended to respond in one of two ways 
when reflecting on their negative gFOBt result, which was dependent 
on their knowledge and acceptance of the limitations associated with 
gFOBt screening. For some, the process of being given a perceived “all 
clear” followed by a colorectal cancer diagnosis led to some degree of 
uncertainty regarding the accuracy of their test result and a loss of 
confidence in the screening programme (subtheme). In contrast, oth-
ers reported that they understood that the gFOB test was not 100% 
effective and was not a guarantee that they did not have or would 
not develop cancer in the future, recognizing the importance of moni-
toring symptoms and recalling the disclaimer that accompanies the 
screening result letter.
I will admit when I was told what I had, I thought oh “so 
much for your bloody test”, but I mean that was it, just left 
it at that… but it’s like everything else erm what a terrible 
thing to say but don’t put a great store in what these sam-
ples say… 
(Female, Tayside #01)
I mean the fact that I took, I… I had the sticks [gFOBt 
screening test], um, made me think to myself, you know, 
it did make… it has made me wonder now how good the 
sticks are? 
(Female, Tayside #13)
You know it comes down to personal responsibility, you get 
the negative result, you are told that if you have any symp-
toms, now I did have symptoms the bleeding but I chose to 
ignore it because I thought it was something else. 
(Female, Tayside #04)
Overall, interviewees remained very positive towards colorectal can-
cer screening and the associated benefits and showed a willingness for 
continued participation, including encouraging others to participate in 
the programmes.
Let’s just say I’ll still keep in with the screening programme 
but I won’t have the same feeling of certainty about it. 
(Female, Tayside #03)
4  | DISCUSSION
4.1 | Principal findings
In this study, we examined whether the receipt of a negative gFOBt 
result contributed to the pathway to diagnosis among screening 
participants subsequently diagnosed with an interval colorectal 
cancer. Patient accounts highlighted the variability and complex-
ity of presenting symptom type and contributing factors that influ-
enced the patient interval. Participants placed a high level of trust 
in their screening gFOBt result, interpreting it as an “all clear” and 
seldom questioned the reliability of the result or the limitations of 
the screening test when they received their result letter. The major-
ity of participants did not consider their previous gFOBt result (nor 
consider a potential colorectal cancer diagnosis) following the onset 
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of symptoms, and therefore, reassurance from a negative gFOBt 
did not contribute to a delay in the patient interval. However, for 
a smaller group of patients who did consider colorectal cancer as 
a possible cause of their symptoms (or were experiencing symp-
toms intermittently or at the time they completed their screening 
test), a negative gFOBt result did influence the patient interval and 
contributed to a delay in seeking help. A negative gFOBt result led 
participants to “downplay” the seriousness of their symptoms by 
reducing their cancer suspicion and reinforcing “benign” causal be-
liefs having been reassured by a recent “all clear” test result. Pre- 
existing conditions, particularly when the characteristics of any 
new symptoms were similar to those previously experienced, led 
to some delay across the symptom appraisal, help- seeking and di-
agnostic interval.15
4.2 | Comparison with existing literature
The processes within the appraisal interval as part of the Model 
of Pathways to Treatment,15 namely “patient appraisal and self- 
management,” draw on a number of psychological theories includ-
ing Leventhal’s Common Sense Model of Illness self- regulation and 
the Andersen Model of Total Patient Delay.16,28 Consistent with our 
findings, Leventhal’s model explains that initial symptom appraisal, 
or recognition of a bodily change, when symptoms do not exceed a 
certain level of interference, leads to symptoms being normalized 
or dismissed. However, when symptoms persisted, or increased in 
severity (eg exceeded a threshold of interference), patients adopted 
a different approach where they self- monitored their symptoms or 
sought self- treatments prior to making the decision to seek medical 
advice. Furthermore, as reported in the literature, we found that 
many participants did not attribute their symptoms to a potential 
cancer diagnosis despite some experiencing a colorectal cancer 
“alarm” symptom, for example blood in stool.2
Lack of recognition of the seriousness of a symptom has been 
reported extensively in the literature as one of the main contrib-
uting factors to a delayed patient interval.18,19 In both the present 
study and the study carried out by Solbjor and colleagues exam-
ining interval breast cancers following mammography screening, 
a negative screening result was shown to impact on the patient 
interval primarily through reassurance which led some participants 
to “downplay” the seriousness of their symptoms and to assume a 
benign cause.26 Hall and colleagues found that a negative screening 
result, along with a number of other factors including absence of 
blood or pain, or “feeling well,” was viewed as reassuring.23 In the 
same way, reassurance from a previous “all clear” investigation has 
been associated with a delay in help- seeking even when symptoms 
persisted or occurred a number of years later with some patients 
believing that they would not be taken seriously if they returned 
with similar symptoms.20,21 The added complexity of the presence 
of comorbidities (or competing diagnoses) and the associated delay 
on the diagnostic pathway potentially resulting in late- stage dis-
ease is an important and recognized challenge for healthcare pro-
viders,29,30 particularly in the light of the recent evidence published 
by Torring and colleagues who report any delay to the primary care 
interval to be associated with more advanced colorectal cancer.31
Interval colorectal cancer has been shown to have an adverse 
effect on trust in FOBt screening, with the same study reporting 
poorer quality of life among interval cancer patients when com-
pared to those with screen- detected disease.32 Similarly, this has 
been demonstrated in mammography screening where a diagno-
sis of an interval breast cancer influenced patient’s trust, although 
not to the point of creating distrust, where women instead saw 
themselves as exceptions in an otherwise beneficial screening 
programme.33 We also found that despite some interviewees sug-
gesting a loss of confidence in the screening programme following 
their diagnosis, participants generally remained positive towards 
the overall benefits of screening and expressed a willingness for 
continued participation.
4.3 | Strengths and limitations
Participants were recruited from hospitals in both Scotland and 
England, providing narratives from cancer patients who participated 
in different area- based bowel screening programmes. Carrying out 
semi- structured interviews within six months of diagnosis permit-
ted an in- depth exploration of the participant’s pathway to diagno-
sis; nevertheless, accounts are retrospective and therefore subject 
to recall and framing bias. We did not have access to any clinical or 
demographic information for those who declined to be interviewed, 
nor the number that the hospitals did not consider eligible to con-
tact: their experiences and perspectives may differ.
4.4 | Implications for practice and policy
Although reassurance from a negative gFOBt result is appropriate 
for most screening participants, there is a risk of over- reassurance 
for some. Methods of increasing understanding of the limitations of 
gFOBt screening (and indeed of FIT screening) and the ongoing risk 
of developing cancer despite receiving a negative test result are 
needed; the significance of any associated delay in seeking medical 
advice in terms of clinical outcomes also merits further explora-
tion. Similarly, finding effective ways to engage with screening par-
ticipants that complement existing initiatives in primary care with 
regard to symptom vigilance and prompt help- seeking behaviour 
remains an important challenge; there is a need to develop nuanced 
health messages to inform screening participants of the importance 
of help- seeking for vague as well as alarm symptoms following a 
negative test result, particularly in the presence of comorbidities. 
The use of FIT as a diagnostic tool in primary should allow more 
streamlined diagnostic pathways for all patients.34
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